Skip to main content
Top
Published in: Cardiology and Therapy 1/2017

Open Access 01-06-2017 | Review

Management of Hypertension Using Olmesartan Alone or in Combination

Authors: Xiaoshen Zhang, Han Zhang, Yuxia Ma, Wenliang Che, Michael R. Hamblin

Published in: Cardiology and Therapy | Issue 1/2017

Login to get access

Abstract

Hypertension is one of the most significant and consistent risk factors for many cardiovascular diseases. The global prevalence of hypertension has dramatically increased over recent years. Life-style and genetic factors are generally considered to be primarily responsible for the incidence of hypertension. Concerning the high morbidity rate, setting up an updated standard for hypertensive patients becomes indispensable. According to the widely accepted standard treatments for hypertension, these four basic principles should be taken into account: low dosage; medication should provide long term-control; combination therapies are becoming common; personalized treatments are a newer approach. In most patients with hypertension, adequate control of BP can be achieved with combined therapy. Therefore, antihypertensive agents with complementary mechanisms are now recommended. In this review, we focus on the pharmacology, antihypertensive efficacy, and adverse events (AEs) of olmesartan medoxomil, either alone or in combination with other antihypertensive medications. In conclusion, olmesartan medoxomil, is an angiotensin II receptor blocker with an excellent efficacy in the reduction and stabilization of blood pressure. When combined with calcium channel blockers (CCBs) and diuretics, olmesartan medoxomil has a better effect on controlling BP and reducing AEs in patients.
Literature
2.
go back to reference Lim SS, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–60.PubMedPubMedCentralCrossRef Lim SS, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–60.PubMedPubMedCentralCrossRef
3.
go back to reference Collaborators, G.B.D.R.F., et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386(10010):2287–323. Collaborators, G.B.D.R.F., et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386(10010):2287–323.
4.
go back to reference Kearney PM, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.PubMedCrossRef Kearney PM, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.PubMedCrossRef
5.
go back to reference Ong KL, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49(1):69–75.PubMedCrossRef Ong KL, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49(1):69–75.PubMedCrossRef
6.
go back to reference Wolf-Maier K, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289(18):2363–9.PubMedCrossRef Wolf-Maier K, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289(18):2363–9.PubMedCrossRef
7.
go back to reference Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9):1207–25.PubMedCrossRef Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9):1207–25.PubMedCrossRef
9.
go back to reference Chobanian AV, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.PubMedCrossRef Chobanian AV, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.PubMedCrossRef
10.
go back to reference Safar ME, Struijker-Boudier HA. New goals in hypertension management: target-organ protection beyond blood pressure lowering. Drugs 2003;63(Spec No 1):45–7. Safar ME, Struijker-Boudier HA. New goals in hypertension management: target-organ protection beyond blood pressure lowering. Drugs 2003;63(Spec No 1):45–7.
11.
go back to reference Bramlage P, et al. Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice. Vasc Health Risk Manag. 2015;11:1–8.PubMed Bramlage P, et al. Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice. Vasc Health Risk Manag. 2015;11:1–8.PubMed
12.
go back to reference Chobanian AV, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.PubMedCrossRef Chobanian AV, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.PubMedCrossRef
13.
go back to reference Mancia G, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–536.PubMed Mancia G, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462–536.PubMed
14.
go back to reference Ogihara T, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009;32(1):3–107.PubMed Ogihara T, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009;32(1):3–107.PubMed
15.
go back to reference Marks LS, Maxwell MH. Tigerstedt and the discovery of renin. An historical note. Hypertension. 1979;1(4):384–8.PubMedCrossRef Marks LS, Maxwell MH. Tigerstedt and the discovery of renin. An historical note. Hypertension. 1979;1(4):384–8.PubMedCrossRef
17.
18.
go back to reference Yee AH, Burns JD, Wijdicks EF. Cerebral salt wasting: pathophysiology, diagnosis, and treatment. Neurosurg Clin N Am. 2010;21(2):339–52.PubMedCrossRef Yee AH, Burns JD, Wijdicks EF. Cerebral salt wasting: pathophysiology, diagnosis, and treatment. Neurosurg Clin N Am. 2010;21(2):339–52.PubMedCrossRef
19.
20.
go back to reference Unger T. The role of the renin–angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89(2, Supplement 1):3–9. Unger T. The role of the renin–angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89(2, Supplement 1):3–9.
21.
go back to reference Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin–angiotensin systems. Physiol Rev. 2006;86(3):747–803.PubMedCrossRef Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin–angiotensin systems. Physiol Rev. 2006;86(3):747–803.PubMedCrossRef
24.
go back to reference Timmermans PB, et al. Nonpeptide angiotensin II receptor antagonists: a novel class of antihypertensive agents. Blood Vessels. 1990;27(2–5):295–300.PubMed Timmermans PB, et al. Nonpeptide angiotensin II receptor antagonists: a novel class of antihypertensive agents. Blood Vessels. 1990;27(2–5):295–300.PubMed
25.
go back to reference Michel MC, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013;65(2):809–48.PubMedCrossRef Michel MC, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013;65(2):809–48.PubMedCrossRef
26.
go back to reference Ishizuka T, et al. Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism. Drug Metab Dispos. 2012;40(2):374–80.PubMedCrossRef Ishizuka T, et al. Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism. Drug Metab Dispos. 2012;40(2):374–80.PubMedCrossRef
27.
go back to reference Ciulla MM, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation. 2004;110(5):552–7.PubMedCrossRef Ciulla MM, et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation. 2004;110(5):552–7.PubMedCrossRef
28.
go back to reference Ruilope LM, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005;27(5):578–87.PubMedCrossRef Ruilope LM, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther. 2005;27(5):578–87.PubMedCrossRef
29.
go back to reference Fuchs FD. The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment? Evid Based Med. 2013;18(2):44–7.PubMedCrossRef Fuchs FD. The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment? Evid Based Med. 2013;18(2):44–7.PubMedCrossRef
30.
go back to reference Lithell H, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875–86.PubMedCrossRef Lithell H, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875–86.PubMedCrossRef
31.
go back to reference Telmisartan Randomised AssessmeNt Study in A.C.E.i.s.w.c.D.I., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174–83.CrossRef Telmisartan Randomised AssessmeNt Study in A.C.E.i.s.w.c.D.I., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174–83.CrossRef
33.
go back to reference NS Group, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010. 362(16):1477–90. NS Group, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010. 362(16):1477–90.
34.
go back to reference Imai E, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54(12):2978–86.PubMedPubMedCentralCrossRef Imai E, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54(12):2978–86.PubMedPubMedCentralCrossRef
36.
go back to reference Investigators O, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.CrossRef Investigators O, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.CrossRef
37.
go back to reference Fuchs FD, DiNicolantonio JJ. Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand? Open Heart. 2015;2(1):e000236.PubMedPubMedCentralCrossRef Fuchs FD, DiNicolantonio JJ. Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand? Open Heart. 2015;2(1):e000236.PubMedPubMedCentralCrossRef
38.
go back to reference Bangalore S, et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147,020 patients from randomised trials. BMJ. 2011;342:d2234.PubMedPubMedCentralCrossRef Bangalore S, et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147,020 patients from randomised trials. BMJ. 2011;342:d2234.PubMedPubMedCentralCrossRef
39.
go back to reference van Vark LC, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088–97.PubMedPubMedCentralCrossRef van Vark LC, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088–97.PubMedPubMedCentralCrossRef
40.
go back to reference Cheng J, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174(5):773–85.PubMedCrossRef Cheng J, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014;174(5):773–85.PubMedCrossRef
41.
go back to reference Elgendy IY, et al. Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials. Am J Hypertens. 2015;28(5):576–85.PubMedCrossRef Elgendy IY, et al. Efficacy and safety of angiotensin receptor blockers in older patients: a meta-analysis of randomized trials. Am J Hypertens. 2015;28(5):576–85.PubMedCrossRef
43.
go back to reference Calhoun DA, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54(1):32–9.PubMedCrossRef Calhoun DA, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54(1):32–9.PubMedCrossRef
44.
go back to reference Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl. 2001;19(1):S21–32.PubMedCrossRef Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl. 2001;19(1):S21–32.PubMedCrossRef
45.
go back to reference Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008;68(9):1239–72.PubMedCrossRef Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008;68(9):1239–72.PubMedCrossRef
46.
go back to reference Ma SF, et al. Hydrolysis of angiotensin II receptor blocker prodrug olmesartan medoxomil by human serum albumin and identification of its catalytic active sites. Drug Metab Dispos. 2005;33(12):1911–9.PubMed Ma SF, et al. Hydrolysis of angiotensin II receptor blocker prodrug olmesartan medoxomil by human serum albumin and identification of its catalytic active sites. Drug Metab Dispos. 2005;33(12):1911–9.PubMed
49.
go back to reference Chrysant SG, Chavanu KJ, Xu J. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. Am J Cardiovasc Drugs. 2009;9(4):241–51.PubMedCrossRef Chrysant SG, Chavanu KJ, Xu J. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. Am J Cardiovasc Drugs. 2009;9(4):241–51.PubMedCrossRef
50.
go back to reference Chrysant SG, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17(3):252–9.PubMedCrossRef Chrysant SG, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens. 2004;17(3):252–9.PubMedCrossRef
51.
go back to reference Kumbla DK, et al. WIN OVER study: efficacy and safety of olmesartan in Indian hypertensive patients: results of an open-label, non-comparative, multi-centric, post marketing observational study. Indian Heart J. 2014;66(3):340–4.PubMedPubMedCentralCrossRef Kumbla DK, et al. WIN OVER study: efficacy and safety of olmesartan in Indian hypertensive patients: results of an open-label, non-comparative, multi-centric, post marketing observational study. Indian Heart J. 2014;66(3):340–4.PubMedPubMedCentralCrossRef
52.
go back to reference Bohm M, Ewald S, Olmebest Study A. Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open-label sub-study in German patients. Curr Med Res Opin. 2006;22(7):1375–80.PubMedCrossRef Bohm M, Ewald S, Olmebest Study A. Blood pressure reduction with olmesartan in mild-to-moderate essential hypertension: a planned interim analysis of an open-label sub-study in German patients. Curr Med Res Opin. 2006;22(7):1375–80.PubMedCrossRef
53.
go back to reference Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Investig. 2003;23(7):419–30.PubMedCrossRef Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Investig. 2003;23(7):419–30.PubMedCrossRef
54.
go back to reference Oparil S, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(5):283–91, 318. Oparil S, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(5):283–91, 318.
55.
go back to reference Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5(1):41–50.PubMedCrossRef Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5(1):41–50.PubMedCrossRef
56.
go back to reference Chrysant SG, et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J Am Soc Hypertens. 2012;6(2):132–41.PubMedCrossRef Chrysant SG, et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J Am Soc Hypertens. 2012;6(2):132–41.PubMedCrossRef
57.
go back to reference Chrysant SG, Marbury TC, Silfani TN. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monit. 2006;11(3):135–41.PubMedCrossRef Chrysant SG, Marbury TC, Silfani TN. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monit. 2006;11(3):135–41.PubMedCrossRef
58.
go back to reference Omboni S, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild-to-moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials. Drugs Aging. 2012;29(12):981–92.PubMedCrossRef Omboni S, et al. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild-to-moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials. Drugs Aging. 2012;29(12):981–92.PubMedCrossRef
59.
go back to reference Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens. 2002;16(Suppl 2):S24–8.PubMedCrossRef Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens. 2002;16(Suppl 2):S24–8.PubMedCrossRef
60.
go back to reference Wang L, et al. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis. Am J Cardiovasc Drugs. 2012;12(5):335–44.PubMedCrossRef Wang L, et al. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis. Am J Cardiovasc Drugs. 2012;12(5):335–44.PubMedCrossRef
61.
go back to reference Chrysant SG, et al. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens. 2010;24(11):730–8.PubMedPubMedCentralCrossRef Chrysant SG, et al. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens. 2010;24(11):730–8.PubMedPubMedCentralCrossRef
62.
go back to reference Chrysant SG, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587–604.PubMedCrossRef Chrysant SG, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587–604.PubMedCrossRef
63.
go back to reference Derosa G, et al. Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. Inflammation. 2014;37(1):154–62.PubMedCrossRef Derosa G, et al. Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. Inflammation. 2014;37(1):154–62.PubMedCrossRef
64.
go back to reference Derosa G, et al. Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies. J Clin Pharm Ther. 2013;38(1):48–55.PubMedCrossRef Derosa G, et al. Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies. J Clin Pharm Ther. 2013;38(1):48–55.PubMedCrossRef
65.
go back to reference Derosa G, et al. Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. Clin Exp Hypertens. 2013;35(5):301–7.PubMedCrossRef Derosa G, et al. Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. Clin Exp Hypertens. 2013;35(5):301–7.PubMedCrossRef
66.
go back to reference Derosa G, et al. Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur J Pharm Sci. 2014;51:26–33.PubMedCrossRef Derosa G, et al. Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur J Pharm Sci. 2014;51:26–33.PubMedCrossRef
67.
go back to reference Derosa G, et al. Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. J Am Soc Hypertens. 2013;7(1):32–9.PubMedCrossRef Derosa G, et al. Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. J Am Soc Hypertens. 2013;7(1):32–9.PubMedCrossRef
68.
go back to reference Sievers P, et al. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis. Drug Des Devel Ther. 2015;9:3935–42.PubMedPubMedCentral Sievers P, et al. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis. Drug Des Devel Ther. 2015;9:3935–42.PubMedPubMedCentral
69.
go back to reference Agabiti-Rosei E, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50(1):154–60.PubMedCrossRef Agabiti-Rosei E, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007;50(1):154–60.PubMedCrossRef
70.
go back to reference Matsui Y, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension. 2009;54(4):716–23.PubMedCrossRef Matsui Y, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension. 2009;54(4):716–23.PubMedCrossRef
71.
go back to reference Daikuhara H, Kikuchi F, Ishida T. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study. Diab Vasc Dis Res. 2012;9(4):280–6.PubMedCrossRef Daikuhara H, Kikuchi F, Ishida T. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study. Diab Vasc Dis Res. 2012;9(4):280–6.PubMedCrossRef
72.
go back to reference Axthelm C, et al. Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg. Curr Med Res Opin. 2012;28(1):69–78.PubMedCrossRef Axthelm C, et al. Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg. Curr Med Res Opin. 2012;28(1):69–78.PubMedCrossRef
73.
go back to reference Ruilope L, Schaefer A. The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension. Adv Ther. 2013;30(12):1086–99.PubMedPubMedCentralCrossRef Ruilope L, Schaefer A. The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension. Adv Ther. 2013;30(12):1086–99.PubMedPubMedCentralCrossRef
74.
go back to reference Ruilope LM, Investigators SS. Fixed-combination olmesartan/amlodipine was superior to perindopril + amlodipine in reducing central systolic blood pressure in hypertensive patients with diabetes. J Clin Hypertens (Greenwich). 2016;18(6):528–35.CrossRef Ruilope LM, Investigators SS. Fixed-combination olmesartan/amlodipine was superior to perindopril + amlodipine in reducing central systolic blood pressure in hypertensive patients with diabetes. J Clin Hypertens (Greenwich). 2016;18(6):528–35.CrossRef
75.
go back to reference Oparil S, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7):1252–69.PubMedCrossRef Oparil S, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7):1252–69.PubMedCrossRef
76.
go back to reference Pickering TG, et al. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens. 2010;4(2):56–61.PubMedCrossRef Pickering TG, et al. When and how to use self (home) and ambulatory blood pressure monitoring. J Am Soc Hypertens. 2010;4(2):56–61.PubMedCrossRef
77.
go back to reference Kereiakes DJ, et al. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovasc Diabetol. 2012;11:134.PubMedPubMedCentralCrossRef Kereiakes DJ, et al. Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovasc Diabetol. 2012;11:134.PubMedPubMedCentralCrossRef
78.
go back to reference Roth EM, et al. Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis. J Clin Hypertens (Greenwich). 2013;15(8):584–92.CrossRef Roth EM, et al. Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis. J Clin Hypertens (Greenwich). 2013;15(8):584–92.CrossRef
79.
go back to reference Chrysant SG, et al. Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study. Am J Cardiovasc Drugs. 2012;12(4):233–43.PubMedCrossRef Chrysant SG, et al. Triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study. Am J Cardiovasc Drugs. 2012;12(4):233–43.PubMedCrossRef
80.
go back to reference Sakata Y, et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J. 2015;36(15):915–23.PubMedPubMedCentralCrossRef Sakata Y, et al. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J. 2015;36(15):915–23.PubMedPubMedCentralCrossRef
81.
go back to reference Jung HW, et al. A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naive or non-responders to anti-hypertensive monotherapy (ACE-HY study). Clin Exp Hypertens. 2015;37(6):482–9.PubMedCrossRef Jung HW, et al. A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naive or non-responders to anti-hypertensive monotherapy (ACE-HY study). Clin Exp Hypertens. 2015;37(6):482–9.PubMedCrossRef
82.
go back to reference Mohan JC, et al. Short term safety and tolerability of a fixed dose combination of olmesartan, amlodipine and hydrochlorothiazide. J Clin Diagn Res. 2015;9(8):OC10–3. Mohan JC, et al. Short term safety and tolerability of a fixed dose combination of olmesartan, amlodipine and hydrochlorothiazide. J Clin Diagn Res. 2015;9(8):OC10–3.
83.
go back to reference Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol. 2001;87(8A):37C–43C.PubMedCrossRef Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol. 2001;87(8A):37C–43C.PubMedCrossRef
84.
go back to reference Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens Suppl. 2001;19(1):S49–56.PubMedCrossRef Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens Suppl. 2001;19(1):S49–56.PubMedCrossRef
85.
go back to reference Benicar HCT prescribing information. Revised 07/2013. Daiichi Sankyo, I.R.I.A.f.U.h.w.a.f.g.d.d.l.s.l.p. and A.S. 23. Benicar HCT prescribing information. Revised 07/2013. Daiichi Sankyo, I.R.I.A.f.U.h.w.a.f.g.d.d.l.s.l.p. and A.S. 23.
86.
go back to reference Galanopoulos M, et al. Small bowel enteropathy associated with olmesartan medoxomil treatment. Ann Gastroenterol. 2017;30(1):131–3.PubMed Galanopoulos M, et al. Small bowel enteropathy associated with olmesartan medoxomil treatment. Ann Gastroenterol. 2017;30(1):131–3.PubMed
88.
go back to reference Kulai T, et al. Duodenal villous atrophy in a TTG-negative patient taking olmesartan: a case report and review of the literature. Can J Gastroenterol Hepatol. 2016;2016:6091571.PubMedPubMedCentralCrossRef Kulai T, et al. Duodenal villous atrophy in a TTG-negative patient taking olmesartan: a case report and review of the literature. Can J Gastroenterol Hepatol. 2016;2016:6091571.PubMedPubMedCentralCrossRef
90.
go back to reference Desruisseaux C, et al. Adding water to the mill: olmesartan-induced collagenous sprue—a case report and brief literature review. Can J Gastroenterol Hepatol. 2016;2016:4837270.PubMedPubMedCentralCrossRef Desruisseaux C, et al. Adding water to the mill: olmesartan-induced collagenous sprue—a case report and brief literature review. Can J Gastroenterol Hepatol. 2016;2016:4837270.PubMedPubMedCentralCrossRef
92.
go back to reference DeGaetani M, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108(5):647–53.PubMedCrossRef DeGaetani M, et al. Villous atrophy and negative celiac serology: a diagnostic and therapeutic dilemma. Am J Gastroenterol. 2013;108(5):647–53.PubMedCrossRef
93.
go back to reference Burbure N, et al. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127–34.PubMedCrossRef Burbure N, et al. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127–34.PubMedCrossRef
95.
go back to reference Ianiro G, et al. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40(1):16–23.PubMedCrossRef Ianiro G, et al. Systematic review: sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014;40(1):16–23.PubMedCrossRef
96.
go back to reference Rubio-Tapia A. Sprue-like enteropathy associated with olmesartan—broadening the differential diagnosis of enteropathy. Aliment Pharmacol Ther. 2014;40(11–12):1362–3.PubMedCrossRef Rubio-Tapia A. Sprue-like enteropathy associated with olmesartan—broadening the differential diagnosis of enteropathy. Aliment Pharmacol Ther. 2014;40(11–12):1362–3.PubMedCrossRef
97.
go back to reference Marthey L, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014;40(9):1103–9.PubMedCrossRef Marthey L, et al. Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014;40(9):1103–9.PubMedCrossRef
99.
go back to reference Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 2010;141(2):122–31.PubMedCrossRef Thayer JF, Yamamoto SS, Brosschot JF. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol. 2010;141(2):122–31.PubMedCrossRef
100.
go back to reference Saruta T, et al. Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability. Hypertens Res. 2015;38(2):132–6.PubMedCrossRef Saruta T, et al. Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability. Hypertens Res. 2015;38(2):132–6.PubMedCrossRef
101.
go back to reference Al-Majed AR, et al. Losartan: comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2015;40:159–94.PubMedCrossRef Al-Majed AR, et al. Losartan: comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2015;40:159–94.PubMedCrossRef
102.
go back to reference Lacourciere Y, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther. 2005;27(7):1013–21.PubMedCrossRef Lacourciere Y, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther. 2005;27(7):1013–21.PubMedCrossRef
104.
go back to reference Brunner HR. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens. 1997;10(12 Pt 2):311S–7S.PubMedCrossRef Brunner HR. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens. 1997;10(12 Pt 2):311S–7S.PubMedCrossRef
105.
go back to reference Neutel JM, et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens. 2008;22(4):266–74.PubMedCrossRef Neutel JM, et al. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens. 2008;22(4):266–74.PubMedCrossRef
106.
go back to reference Bottorff MB, Tenero DM. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy. 1999;19(4 Pt 2):73S–8S.PubMedCrossRef Bottorff MB, Tenero DM. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy. 1999;19(4 Pt 2):73S–8S.PubMedCrossRef
107.
go back to reference Gavras I, Gavras H. Safety and tolerability of eprosartan. Pharmacotherapy. 1999;19(4 Pt 2):102S–7S.PubMedCrossRef Gavras I, Gavras H. Safety and tolerability of eprosartan. Pharmacotherapy. 1999;19(4 Pt 2):102S–7S.PubMedCrossRef
108.
go back to reference Chopra A. Molecular imaging and contrast agent database (MICAD), In: 11C-labeled telmisartan, an angiotensin II type 1 receptor antagonist. MD: National Center for Biotechnology Information, NLM, Bethesda; 2004. Chopra A. Molecular imaging and contrast agent database (MICAD), In: 11C-labeled telmisartan, an angiotensin II type 1 receptor antagonist. MD: National Center for Biotechnology Information, NLM, Bethesda; 2004.
109.
go back to reference Zheng Z, Lin S, Shi H. A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension. J Clin Hypertens (Greenwich). 2010;12(6):414–21.CrossRef Zheng Z, Lin S, Shi H. A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension. J Clin Hypertens (Greenwich). 2010;12(6):414–21.CrossRef
110.
go back to reference Gardner SF, Franks AM. Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann Pharmacother. 2003;37(1):99–105.PubMedCrossRef Gardner SF, Franks AM. Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann Pharmacother. 2003;37(1):99–105.PubMedCrossRef
111.
go back to reference Mire DE, Silfani TN, Pugsley MK. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2005;46(5):585–93.PubMedCrossRef Mire DE, Silfani TN, Pugsley MK. A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol. 2005;46(5):585–93.PubMedCrossRef
112.
go back to reference Park JB, et al. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study. Am J Cardiovasc Drugs. 2013;13(1):47–56.PubMedPubMedCentralCrossRef Park JB, et al. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study. Am J Cardiovasc Drugs. 2013;13(1):47–56.PubMedPubMedCentralCrossRef
113.
go back to reference Ghim JL, et al. Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects. J Clin Pharmacol. 2016;56(5):576–80.PubMedCrossRef Ghim JL, et al. Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects. J Clin Pharmacol. 2016;56(5):576–80.PubMedCrossRef
114.
go back to reference Zaiken K, Cheng JW. Azilsartan medoxomil: a new angiotensin receptor blocker. Clin Ther. 2011;33(11):1577–89.PubMedCrossRef Zaiken K, Cheng JW. Azilsartan medoxomil: a new angiotensin receptor blocker. Clin Ther. 2011;33(11):1577–89.PubMedCrossRef
Metadata
Title
Management of Hypertension Using Olmesartan Alone or in Combination
Authors
Xiaoshen Zhang
Han Zhang
Yuxia Ma
Wenliang Che
Michael R. Hamblin
Publication date
01-06-2017
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 1/2017
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-017-0087-5

Other articles of this Issue 1/2017

Cardiology and Therapy 1/2017 Go to the issue